PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Neonatal Discontinuation Syndrome in Serotonergic Antidepressant-Exposed Neonates.

Abstract To determine whether infants exposed in utero to serotonin reuptake inhibitor (SRI) antidepressants or a DSM-IV-TR-defined mood disorder have significantly more neonatal discontinuation signs compared to an unexposed group of infants at 2-4 weeks after birth.
PMID
Related Publications

Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications.

Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.

Prenatal antidepressant exposure associated with CYP2E1 DNA methylation change in neonates.

Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates.

Mother-infant antidepressant concentrations, maternal depression, and perinatal events.

Authors

Mayor MeshTerms
Keywords
Journal Title the journal of clinical psychiatry
Publication Year Start




PMID- 28570796
OWN - NLM
STAT- In-Process
DA  - 20170601
LR  - 20170601
IS  - 1555-2101 (Electronic)
IS  - 0160-6689 (Linking)
VI  - 78
IP  - 5
DP  - 2017 May
TI  - Neonatal Discontinuation Syndrome in Serotonergic Antidepressant-Exposed
      Neonates.
PG  - 605-611
LID - 10.4088/JCP.16m11044 [doi]
LID - 16m11044 [pii]
AB  - OBJECTIVE: To determine whether infants exposed in utero to serotonin reuptake
      inhibitor (SRI) antidepressants or a DSM-IV-TR-defined mood disorder have
      significantly more neonatal discontinuation signs compared to an unexposed group 
      of infants at 2-4 weeks after birth. METHODS: This secondary analysis was derived
      from 2 observational studies with enrollment from July 2000 to December 2011 in
      Cleveland, Ohio, and Pittsburgh, Pennsylvania. Mothers (n = 214) belonged to one 
      of 3 groups based on exposure status during pregnancy: (1) Comparison-women who
      did not take psychotropics during pregnancy and had no major mood disorder; (2)
      SRI-exposed-women with a mood disorder who were taking an SRI but no
      benzodiazepines; and (3) Mood Disorder-women with depression or bipolar disorder 
      who did not take psychotropic medications. The infants were examined for signs
      according to the Finnegan Scale by evaluators blind to maternal exposure status. 
      RESULTS: The rates of sign presence (defined as a score >/= 2 on the Finnegan
      Scale) in the SRI, Mood Disorder, and Comparison groups were similar at 34.1%,
      35.1%, and 30.4%, respectively. Women in the SRI group had a significantly higher
      preterm birth rate (24.4%) compared to the other 2 groups (7.4% and 8.9% in the
      Mood Disorder and Comparison groups, respectively; P = .012). Preterm newborns
      had a significantly higher sign rate compared to full-term newborns (54% vs 31%, 
      P = .020). We observed a significant relationship between Finnegan signs and
      preterm birth. CONCLUSIONS: The presence of neonatal signs at 2-4 weeks was more 
      closely associated with prematurity than with in utero SRI or mood disorder
      exposure. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT00279370 and
      NCT00585702.
FAU - Yang, Amy
AU  - Yang A
AD  - Biostatistics Collaboration Center, Department of Preventive Medicine Feinberg
      School of Medicine Northwestern University, Chicago, Illinois, USA.
FAU - Ciolino, Jody D
AU  - Ciolino JD
AD  - Biostatistics Collaboration Center, Department of Preventive Medicine Feinberg
      School of Medicine Northwestern University, Chicago, Illinois, USA.
FAU - Pinheiro, Emily
AU  - Pinheiro E
AD  - Asher Center for the Study and Treatment of Depressive Disorders Department of
      Psychiatry and Behavioral Sciences, Northwestern University, Chicago, Illinois,
      USA.
FAU - Rasmussen-Torvik, Laura J
AU  - Rasmussen-Torvik LJ
AD  - Department of Preventive Medicine, Northwestern University, Chicago, Illinois,
      USA.
FAU - Sit, Dorothy K Y
AU  - Sit DKY
AD  - Department of Psychiatry and Behavioral Science Feinberg School of Medicine,
      Northwestern University, Chicago, Illinois, USA.
FAU - Wisner, Katherine L
AU  - Wisner KL
AD  - Asher Center for the Study and Treatment of Depressive Disorders Northwestern
      University Feinberg School of Medicine, 676 North Saint Clair St, Ste 1000,
      Chicago, IL 60611. [email protected]
AD  - Norman and Helen Asher Professor of Psychiatry and Behavioral Sciences, and
      Obstetrics and Gynecology, Asher Center for the Study and Treatment of Depressive
      Disorders, Northwestern University Feinberg School of Medicine, Chicago,
      Illinois, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00279370
SI  - ClinicalTrials.gov/NCT00585702
PT  - Journal Article
PL  - United States
TA  - J Clin Psychiatry
JT  - The Journal of clinical psychiatry
JID - 7801243
EDAT- 2017/06/02 06:00
MHDA- 2017/06/02 06:00
CRDT- 2017/06/02 06:00
PHST- 2016/06/28 [received]
PHST- 2016/10/20 [accepted]
AID - 10.4088/JCP.16m11044 [doi]
PST - ppublish
SO  - J Clin Psychiatry. 2017 May;78(5):605-611. doi: 10.4088/JCP.16m11044.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>